Seismic Therapeutic to Present Preclinical Data for Novel Immunoglobulin Sculpting Enzyme at AAN Annual Meeting
08 Mar 2024
AACRImmunotherapyClinical Study
WATERTOWN, Mass.--(BUSINESS WIRE)-- Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will present preclinical data for its pan-immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) annual meeting taking place on April 13-18 in Denver.
S-1117 is a novel engineered pan-IgG protease for the potential treatment of a range of chronic and acute autoantibody mediated diseases, including the chronic neuromuscular autoimmune disorder, myasthenia gravis. The presentation at the AAN annual meeting will outline key preclinical in vitro and in vivo results supporting the differentiated pro S-1117 compared to therapeutic benchmarks in chronic autoantibody mediated diseases. S-1117 addresses multiple mechanisms of autoimmunity by lowering IgG and immune complex levels, reducing IgG effector functions and cleaving the antigen receptor (BCR) on memory B cells. Moreover, in a mouse pharmacokinetic model, S-1117 was able to achieve deep, sustained and rapid reduction in human IgG.
Presentation details:
Title: Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Session: P4 - Autoimmune Neurology: Peripheral Autoimmunity
Date: Monday, April 15, 2024
Time: 11:45 a.m. – 12:45 p.m. MT
Area: 14
Poster number: 018
Abstract number: 6869
About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit and follow us on LinkedIn and on X @Seismic_Tx.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.